MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer. "We are thrilled to announce the FDA approval of our ...

MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which includes the next generation neurostimulator and the associated Bluetooth® patient remote and physician programmer. "We are thrilled to announce the FDA approval of our ...

Key Takeaways TradingView Inspire Medical Systems released preliminary results indicated second-quarter and full-year revenue above analysts' estimates. The sleep apnea device maker expects second quarter sales to be 30% higher than a year ago. Inspire sees full-year revenue higher by 26% to 28% from 2023. Inspire Medical Systems (INSP) shares rose Monday after the maker of an implanted device to treat sleep apnea released preliminary results and updated guidance that beat forecasts. The company said it exp ...

Preliminary, Unaudited Second Quarter Revenue Updated Full Year 2024 Revenue Guidance "We are so proud of our team's strong execution and revenue performance in the second quarter, which showed sequential revenue growth acceleration in the U.S.," said Tim Herbert, Chairman and CEO of Inspire. "With the strong momentum we are seeing in our business, we have increased confidence regarding strong continued revenue growth in the second half of 2024. As a result, we are increasing our revenue guidance to $788 mi ...

MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced certain preliminary, unaudited results for the quarter ended June 30, 2024, and updated full year 2024 revenue outlook. The company plans to report its complete results and host its earnings conference call for the second quarter of 202 ...

Stryker, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 10.6%. SYK's earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%. Stryker has gained 17.3% against the industry's 2.9% decline in the past year. Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.5%. BSX's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.5%. Boston S ...

Company Announcement - Inspire Medical Systems announced the appointment of Melissa J Mann as Chief People Officer effective July 22 2024 [1] - Melissa J Mann brings over 25 years of experience in human capital management including 8 years at UnitedHealth Group's Optum division and 13 years at Target Corporation [2] - Melissa J Mann expressed excitement about joining Inspire to help shape the human capital strategy and strengthen the team and culture to fulfill the company's mission of prioritizing patients with untreated obstructive sleep apnea [3] Leadership Transition - Melissa J Mann is replacing Steven L Jandrich who retired in May after 6 years with Inspire during which the company grew to over 1 000 team members [5] - Tim Herbert Chairman and CEO of Inspire highlighted Melissa's vast experience in human capital management as valuable for the company's continued growth and scaling [5] Company Overview - Inspire Medical Systems is a medical technology company focused on developing and commercializing minimally invasive solutions for obstructive sleep apnea [3] - The company's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] Educational Background - Melissa J Mann holds a B A from 1996 and an M B A in Human Resources Management from 2003 both from the University of St Thomas in St Paul Minnesota [5]

MINNEAPOLIS, July 19, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced CE mark certification under the European Union's Medical Device Regulation (EU MDR 2017/745) for Inspire therapy. "Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, ...

"Inspire has a long history of compliance to the European Union's (EU) quality system and CE mark requirements, with uninterrupted CE mark approval since 2010," said Tim Herbert, Chairman and President of Inspire. "The Inspire team has worked diligently with our notified body in Europe to complete the review process, which included obtaining temporary approval through derogation authorization to continue to deliver Inspire product in several countries." There are two changes to Inspire therapy that are now ...

Core Insights - Inspire Medical Systems has received approval from the European Union Medical Device Regulation (EU MDR) for additional MRI scan conditions, expanding its therapy's use to include full-body MRI scans, which were previously limited to head, neck, and extremity scans [1][2] - This approval is retroactive, benefiting all patients with the Inspire IV neurostimulator device that was introduced in 2018 [1] - The full-body MRI compatibility has been a significant advantage for patients in the United States for the past two years, and this new approval aims to provide similar benefits for patients in Europe [2][6] Company Overview - Inspire Medical Systems is focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA) [3] - The company's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] Market Impact - The expansion of MRI compatibility is expected to alleviate concerns for patients considering Inspire therapy, potentially increasing the adoption of the therapy among those who struggle with CPAP [2][6] - Millions of MRIs are performed annually in Europe for various medical evaluations, indicating a substantial market opportunity for Inspire's expanded therapy use [2]